SCHEMBL5142203

SCHEMBL5142203

Cc1ccccc1-c1cncc(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.44
METAP2 P50579 1/20 0.44
ATP4A P20648 2/20 0.40
ATP4B P51164 2/20 0.40
DCUN1D1 Q96GG9 2/20 0.40
CDK2 P24941 2/20 0.40
GPBAR1 Q8TDU6 1/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
CYP1A2 P05177 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
CYP2C19 P33261 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CASP3 P42574 2/20 0.37
SENP8 Q96LD8 2/20 0.37
SENP7 Q9BQF6 2/20 0.37
SENP6 Q9GZR1 2/20 0.37
PRKDC P78527 1/20 0.37
ATR Q13535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17204488 0.91 IDO1 (0.38) IDO1METAP2ATP4AATP4BDCUN1D1
O-Xylene SCHEMBL27600417 0.80 ACHE (0.48) CDK2GPBAR1CYP1A2CYP2C19MEN1
SCHEMBL3366129 0.78 ALOX5AP (0.45) IDO1METAP2ATP4AATP4BNPC1
SCHEMBL1782451 0.78 IDO1 (0.44) IDO1DCUN1D1CDK2RAB9ACYP1A2
SCHEMBL27814299 0.77 HSP90AA1 (0.55) METAP2ATP4AATP4BDCUN1D1CYP1A2
SCHEMBL20415004 0.76 AGPAT2 (0.45) IDO1MEN1KMT2AALDH1A1CYP3A4
SCHEMBL25593137 0.76 PLA2G7 (0.46) IDO1CDK2RAB9ASMN1; SMN2CASP3
SCHEMBL10304960 0.75 IDO1 (0.42) IDO1METAP2ATP4AATP4BKDM4E
SCHEMBL28352850 0.74 IDO1 (0.50) IDO1CYP2D6
SCHEMBL319173 0.72 CDK2 (0.48) CDK2NPC1RAB9ACYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363702-A4 METHODS OF INHIBITING KINASES CYTOPIA PTY LTD (AU) 2007-08-22 EP disclosed
US-20060069084-A1 Methods of inhibiting kinases CYTOPIA RESEARCH PTY LTD (AU) 2006-03-30 US disclosed
US-20040102455-A1 Method of inhibiting kinases CYTOPIA RESEARCH PTY LTD (AU) 2004-05-27 US disclosed
EP-1363702-A1 METHODS OF INHIBITING KINASES Cytopia PTY Ltd (AU) 2003-11-26 EP disclosed
WO-2002060492-A1 METHODS OF INHIBITING KINASES CYTOPIA PTY LTD (AU) 2002-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102455-A1 Method of inhibiting kinases JAK2, JAK1, JAK3 IDO1 581/4885METAP2 1923/4885ATP4A 4541/4885
US-20060069084-A1 Methods of inhibiting kinases JAK2, JAK1, JAK3 IDO1 661/4885METAP2 1985/4885ATP4A 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.